CA2998422A1 - Formulation having controlled, delayed release of active ingredient - Google Patents

Formulation having controlled, delayed release of active ingredient Download PDF

Info

Publication number
CA2998422A1
CA2998422A1 CA2998422A CA2998422A CA2998422A1 CA 2998422 A1 CA2998422 A1 CA 2998422A1 CA 2998422 A CA2998422 A CA 2998422A CA 2998422 A CA2998422 A CA 2998422A CA 2998422 A1 CA2998422 A1 CA 2998422A1
Authority
CA
Canada
Prior art keywords
active ingredient
release
range
mixture
propranolol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2998422A
Other languages
English (en)
French (fr)
Inventor
Finn BAUER
Thorsten Wedel
Guenter Moddelmog
Gudrun BIRK
Roberto Ognibene
Dieter Lubda
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of CA2998422A1 publication Critical patent/CA2998422A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2998422A 2015-09-14 2016-08-25 Formulation having controlled, delayed release of active ingredient Abandoned CA2998422A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15185028.6 2015-09-14
EP15185028 2015-09-14
EP15189045.6 2015-10-09
EP15189045 2015-10-09
PCT/EP2016/001430 WO2017045742A1 (de) 2015-09-14 2016-08-25 Formulierung mit kontrollierter, verzögerter wirkstoffreisetzung

Publications (1)

Publication Number Publication Date
CA2998422A1 true CA2998422A1 (en) 2017-03-23

Family

ID=56855404

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2998422A Abandoned CA2998422A1 (en) 2015-09-14 2016-08-25 Formulation having controlled, delayed release of active ingredient

Country Status (8)

Country Link
US (2) US10874615B2 (enExample)
EP (1) EP3349733A1 (enExample)
JP (1) JP6841819B2 (enExample)
KR (1) KR20180052126A (enExample)
CN (1) CN108024966A (enExample)
AU (1) AU2016321659A1 (enExample)
CA (1) CA2998422A1 (enExample)
WO (1) WO2017045742A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160235709A1 (en) 2012-08-31 2016-08-18 Molecular product management LLC Limited release lingual thioctic acid delivery systems
EP3519812B1 (en) 2016-09-27 2026-05-06 Zolentroff, William C. Ala and salt formulation
JP7238509B2 (ja) * 2019-03-19 2023-03-14 三菱ケミカル株式会社 医薬錠剤

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0096074A4 (en) * 1981-12-18 1984-05-29 Key Pharma EXPANDABLE MESH OF POLYVINYL ALCOHOL AND POLYETHYLENE GLYCOL.
WO1988007366A1 (en) * 1987-03-25 1988-10-06 E.I. Du Pont De Nemours And Company Use of vinyl alcohol homopolymers and copolymers for tableting active materials
US6495656B1 (en) * 1990-11-30 2002-12-17 Eastman Chemical Company Copolyesters and fibrous materials formed therefrom
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
US5838571A (en) * 1996-01-29 1998-11-17 Alza Corporation Tablet press monitoring and controlling method and apparatus
HUP0301415A2 (hu) * 2000-07-06 2003-09-29 Delsys Pharmaceutical Corporation Eljárás megnövelt stabilitású egészségvédż termékek formulázására
GB0113841D0 (en) * 2001-06-07 2001-08-01 Boots Co Plc Therapeutic agents
US7022342B2 (en) * 2002-03-28 2006-04-04 Andrx Corporation, Inc. Controlled release oral dosage form of beta-adrenergic blocking agents
US20060099256A1 (en) * 2002-11-27 2006-05-11 Price James C Microspheres and related processes and pharmaceutical compositions
US7241838B2 (en) * 2003-12-19 2007-07-10 Eastman Chemical Company Blends of aliphatic-aromatic copolyesters with ethylene-vinyl acetate copolymers
US7368503B2 (en) * 2003-12-22 2008-05-06 Eastman Chemical Company Compatibilized blends of biodegradable polymers with improved rheology
US20080152595A1 (en) * 2004-11-24 2008-06-26 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of orally administered pharmaceutical products
US20090098202A1 (en) * 2006-02-10 2009-04-16 Boehringer Ingelheim International Gmbh Extended Release Formulation
US9238073B2 (en) * 2006-04-12 2016-01-19 Wyeth Llc Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive
WO2009048557A1 (en) * 2007-10-10 2009-04-16 Mallinckrodt Baker, Inc. Directly compressible high functionality granular microcrystalline cellulose based excipient, manufacturing process and use thereof
EP2177213B1 (en) * 2008-09-17 2013-01-02 Siegfried Ltd. Nicotine-containing granulate
AU2010314994B2 (en) * 2009-11-09 2016-10-06 Spotlight Technology Partners Llc Fragmented hydrogels
JP2013241341A (ja) * 2012-05-17 2013-12-05 Nisshin Kasei Kk マトリックス製剤用基剤、及び該基剤を用いた徐放性製剤
GB201412413D0 (en) * 2014-07-11 2014-08-27 Revolymer Uk Ltd Encapsulated benefit agent particles
KR20170038039A (ko) * 2014-07-30 2017-04-05 메르크 파텐트 게엠베하 분상, 직접 압축성 유형의 폴리비닐 알코올

Also Published As

Publication number Publication date
CN108024966A (zh) 2018-05-11
US10874615B2 (en) 2020-12-29
US20200246270A1 (en) 2020-08-06
US20190038562A1 (en) 2019-02-07
KR20180052126A (ko) 2018-05-17
AU2016321659A1 (en) 2018-05-10
WO2017045742A1 (de) 2017-03-23
EP3349733A1 (de) 2018-07-25
JP2018530538A (ja) 2018-10-18
JP6841819B2 (ja) 2021-03-10

Similar Documents

Publication Publication Date Title
JP6629835B2 (ja) 直接圧縮可能なポリビニルアルコール
JP6706245B2 (ja) 微結晶性セルロースを含む直接圧縮可能な組成物
Abdelkader et al. Formulation of controlled-release baclofen matrix tablets: Influence of some hydrophilic polymers on the release rate and in vitro evaluation
AU2024216408B2 (en) Improved bromocriptine formulations
JPWO2008072534A1 (ja) マンニトール又は乳糖を含有する固形製剤
EP2217241B1 (en) Wet granulation using a water sequestering agent
CN107951853B (zh) 一种盐酸普拉克索缓释药物组合物及其制备方法
US20200246270A1 (en) Formulation having controlled, delayed release of active ingredient
US11040012B2 (en) Pulverulent, directly compressible polyvinyl alcohol grades
RS66060B1 (sr) Sastav koji sadrži ramipril i indapamid
JP2026083366A (ja) パーキンソン病治療薬の安定化方法
WO2012139736A1 (en) Pharmaceutical composition comprising bosentan
KR20170008239A (ko) 세리티닙 제제
JP2010001242A (ja) レバミピド固形製剤及びその製造方法
WO2017093890A1 (en) Clobazam tablet formulation and process for its preparation
US20180250233A1 (en) Tablets having media independent active substance delivery
US20160022661A1 (en) Dosage Form Comprising Crizotinib
CA2730112A1 (en) Directly pressed aliskiren tablets
Jire et al. Liquisolid compact tablet: An innovative approach for enhancing bioavailability and solubility
JP2021506750A (ja) アカルボースおよびメトホルミンの固定用量組合せ錠剤製剤およびその製造方法
WO2018130943A1 (en) Oral pharmaceutical composition of lurasidone and preparation thereof
WO2021148362A1 (en) Directly compressible polymer combinations for matrix tablets with extended drug release
WO2025265110A1 (en) Oral pharmaceutical compositions comprising a naphthyridine compound
CN121177242A (zh) 一种具有高稳定性与快速溶出特性的阿法替尼片剂及其制备方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210726

FZDE Discontinued

Effective date: 20240130